(Q33757375)

29 July 2017

1 reference

title

Clinical implications of amylin and amylin deficiency (English)

1 reference

29 July 2017

D F Kruger

1

1 reference

29 July 2017

P M Gatcomb

series ordinal

2

1 reference

29 July 2017

S K Owen

series ordinal

3

1 reference

29 July 2017

1 May 1999

1 reference

The Science of Diabetes Self-Management and Care

29 July 2017

1 reference

29 July 2017

25

1 reference

29 July 2017

3

1 reference

29 July 2017

389-97; quiz 398

1 reference

Natural history of beta-cell dysfunction in NIDDM.

29 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Co-secretion of amylin and insulin from cultured islet β-cells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Structure and biology of amylin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Glucagon and its family revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Reduction of Postprandial Hyperglycemia in Subjects With IDDM by Intravenous Infusion of AC137, a Human Amylin Analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Rapid gastric emptying of a solid pancake meal in type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Highly variable gastric emptying in patients with insulin dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572179902500310

10.1177/014572179902500310

21 January 2018

Identifiers

DOI

0 references

1 reference